35
Participants
Start Date
October 15, 2018
Primary Completion Date
July 1, 2021
Study Completion Date
July 2, 2021
Etrumadenant
Etrumadenant is an A2aR and A2bR antagonist for oral use
IPI-549
IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
Pegylated liposomal doxorubicin (PLD)
Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
nanoparticle albumin-bound paclitaxel (NP)
NP is a microtubule inhibitor for intravenous (IV) use
The Kinghorn Cancer Centre, Darlinghurst
Chris O'Brien Lifehouse, Camperdown
Macquarie University, Macquarie
St. George Private Hospital, Kogarah
Cabrini Hospital, Malvern
Peninsula & South Eastern Haematology and Oncology Group, Frankston
Pindara Private Hospital, Benowa
Maryland Oncology Hematology, PA, Rockville
Virginia Cancer Specialists, PC, Fairfax
Virginia Oncology Associates, Norfolk
Carolina BioOncology Institute, Huntersville
Miami Cancer Institute at Baptist Health, Miami
HealthPartners Institute Cancer Care Center, Saint Paul
Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology, P.A. - Tyler, Tyler
Texas Oncology, P.A. - Fort Worth Cancer Center, Fort Worth
Texas Oncology, P.A. - San Antonio Northeast, San Antonio
Texas Oncology, P.A. - San Antonio Medical Center, San Antonio
Texas Oncology, P.A. - Austin (Midtown), Austin
Rocky Mountain Cancer Centers (Aurora), Aurora
Scottsdale Healthcare Hospitals dba Honor Health Research Institute, Scottsdale
Arizona Clinical Research Center, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
University of California, Los Angeles, Los Angeles
Willamette Valley Cancer Institute and Research Center, Eugene
MultiCare Regional Cancer Center, Tacoma
Medical Oncology Associates dba Summit Cancer Centers, Spokane
Lead Sponsor
Collaborators (1)
Infinity Pharmaceuticals, Inc.
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY